,i #aaeth ,,congress #b;d ,session ,h4 ,r4 #ffjh ,,in ,,the ,,house ,,of ,,representatives ,july #bf1 #bjah,ms4 ,mc,sally 7for herself and ,mr4 ,cramer7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to provide for the development and dissemination of best practice guidelines for using data collected by prescription drug monitoring programs to identify drug diversion and abuse1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,prescription ,drug ,monitoring ,program ,best ,practices ,act of #bjah4 #b4 ,best practice guidelines for using data collected by prescription drug monitoring programs 7a7 ,best practice guidelines ,the ,director of the ,bureau of ,justice ,assistance and the ,director of the ,centers for ,disease ,control and ,prevention1 acting jointly1 shall-- 7#a7 develop best practice guidelines and potential enhancements to facilitate use of and strengthen prescription drug monitoring programs to identify-- 7,a7 unlawful diversion or misuse of controlled substances2 and 7,b7 the potential for harmful drug interactions2 7#b7 include in such guidelines-- 7,a7 data elements that should be included in proactive1 unsolicited reports that are generated and disseminated to authorized users to identify patients at the highest risk for misuse of controlled substances and identify potential inappropriate prescribing trends2 and 7,b7 best practices on treatment options for consideration by prescribers 7or other health care providers7 for prescription drug monitoring programs that include data on prescriptions for medication assisted treatments for substance use disorders and opioid overdose reversal agents2 7#c7 identify potential barriers to implementation of such guidelines and develop recommendations for addressing such barriers 7such as development of standard data elements to be included in proactive or unsolicited reports or whether data on prescriptions for medication assisted treatments for substance use disorders and opioid overdose reversal agents should be included in prescription drug monitoring programs72 and 7#d7 not later than #ab months after the date of the enactment of this ,act1 submit to ,congress a report that includes best practices identified and a proposed plan for disseminating and supporting adoption of such best practices by state prescription drug monitoring programs4 7b7 ,input from relevant stakeholders ,in developing best practice guidelines under subsection 7a71 the ,director of the ,bureau of ,justice ,assistance and the ,director of the ,centers for ,disease ,control and ,prevention1 acting jointly1 shall conduct a public workshop and otherwise engage with relevant stakeholders to help inform the development of best practices to-- 7#a7 identify patients at the highest risk for misuse of controlled substances and identify potential inappropriate prescribing trends2 7#b7 identify potential data elements to include in proactive1 unsolicited reports that are generated and disseminated to authorized users to identify such patients at the highest risk and identify potential inappropriate prescribing trends1 and assess whether data on prescriptions for medication assisted treatments for substance use disorder and opioid overdose reversal agents should be incorporated and specific considerations for prescribers based on such information2 and 7#c7 identify additional enhancements to prescription drug monitoring programs and potential barriers to adoption and recommendations for addressing such barriers4 7c7 ,grants 7#a7 ,in general ,the ,director of the ,bureau of ,justice ,assistance and the ,director of the ,centers for ,disease ,control and ,prevention1 acting jointly1 shall award grants to ,states to support adoption of best practices identified under subsection 7b74 7#b7 ,amount of awards ,the total amount awarded to any ,state under this subsection shall be-- 7,a7 not less than #be1jjj2 and 7,b7 not more than #ej1jjj4 7#c7 ,authorization of appropriations ,to carry out this subsection1 there is authorized to be appropriated #ejj1jjj4 #c4 ,transfer of prescription drug monitoring program data across ,state lines 7a7 ,facilitating adoption of systems by ,states 7#a7 ,in general ,the ,director of the ,bureau of ,justice ,assistance shall facilitate the adoption of the ,,pmp ,inter,connect ,system of the ,national ,boards of ,pharmacy 7or another appropriate system for the transfer of prescription drug monitoring program data across ,state lines7 by all ,states4 7#b7 ,grants 7,a7 ,award ,the ,secretary may award grants to eligible ,states for technical assistance in addressing barriers to the adoption of a system described in paragraph 7#a74 7,b7 ,eligibility ,to be eligible to receive a grant under this paragraph1 a ,state must not have adopted a system described in paragraph 7#a7 as of the date of the grant award4 7,c7 ,period ,the period of a grant under this paragraph shall not exceed #e years4 7,d7 ,amount of awards ,the total amount awarded to any ,state under this paragraph shall be-- 7i7 not less than #ej1jjj2 and 7ii7 not more than #ajj1jjj4 7,e7 ,authorization of appropriations ,to carry out this paragraph1 there is authorized to be appropriated #ejj1jjj4 7b7 ,,gao study 7#a7 ,study ,the ,comptroller ,general of the ,united ,states shall-- 7,a7 conduct a study to determine how efficiently and effectively ,state prescription drug monitoring programs are sharing data pursuant to the ,,pmp ,inter,connect ,system of the ,national ,boards of ,pharmacy 7or other systems72 and 7,b7 submit a report to the ,congress on the results of such study1 including recommendations for the improvement of such sharing4 7#b7 ,response by ,,bja ,not later than #ahj days after the date on which the report under paragraph 7#a7 is submitted to the ,congress1 the ,director of the ,bureau of ,justice ,assistance shall submit a plan to the ,congress for addressing the recommendations in such report4 7c7 ,pilot program for regional sharing of ,,pdmp data 7#a7 ,in general ,the ,assistant ,secretary for ,mental ,health and ,substance ,use1 in consultation with the ,office of the ,national ,coordinator for ,health ,information ,technology1 shall facilitate regional sharing across ,state lines of prescription drug monitoring program data4 7#b7 ,grants 7,a7 ,awards ,in carrying out paragraph 7#a71 the ,assistant ,secretary for ,mental ,health and ,substance ,use shall award grants to ,states 7or a collaboration of ,states7 to facilitate such regional sharing4 7,b7 ,amount of awards per fiscal year ,the total amount awarded under this paragraph with respect to any region per fiscal year shall be-- 7i7 not less than #ajj1jjj2 and 7ii7 not more than #bjj1jjj4 7,c7 ,authorization of appropriations ,to carry out this paragraph1 there is authorized to be appropriated #e1jjj1jjj4